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Abstract
Portal biliopathy (PB) is defined as the presence of 
biliary abnormalities in patients with non-cirrhotic/non-
neoplastic extrahepatic portal vein obstruction (EHPVO) 
and portal cavernoma (PC). The pathogenesis of PB is 
due to ab  extrinseco  compression of bile ducts by PC 
and/or to ischemic damage secondary to an altered 
biliary vascularization in EHPVO and PC. Although 
asymptomatic biliary abnormalities can be frequently 
seen by magnetic resonance cholangiopancreatography 
in patients with PC (77%-100%), only a part of these 
(5%-38%) are symptomatic. Clinical presentation 
includes jaundice, cholangitis, cholecystitis, abdominal 
pain, and cholelithiasis. In this subset of patients is 
required a specific treatment. Different therapeutic 
approaches aimed to diminish portal hypertension 
and treat biliary strictures are available. In order 
to decompress PC, surgical porto-systemic shunt 
or transjugular intrahepatic porto-systemic shunt 
can be performed, and treatment on the biliary 
stenosis includes endoscopic (Endoscopic retro-
grade cholangiopancreatography with endoscopic 
sphincterotomy, balloon dilation, stone extraction, 
stent placement) and surgical (bilioenteric anastomosis, 
cholecystectomy) approaches. Definitive treatment 
of PB often requires multiple and combined inter-
ventions both on vascular and biliary system. Liver 
transplantation can be considered in patients with 
secondary biliary cirrhosis, recurrent cholangitis or 
unsuccessful control of portal hypertension. 
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Therapeutic approaches for portal biliopathy: A systematic 
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therapy; papers about PVT treatment.
A total of 118 articles were initially retrieved. Of 
these, 69 were excluded according to inclusion/exclu-
sion criteria and the remaining 49 papers were 
included in this review (Figure 1).
PATHOGENESIS 
The development of PB in PC is due to two main 
mechanisms: a mechanical compression ab extrinseco 
of bile ducts (mainly hepatic biliary duct and common 
bile duct) by both the PC and the numerous compen-
satory collateral vein circles that arise after EHPVO 
formation, and an ischemic damage secondary to the 
altered vascularization due to EHPVO and PC.
Normally, venous drain of biliary tree is serviced 
by epicholedochal venous plexus of Saint and the 
paracholedochal plexus of Petren, whom normally 
diameter does not exceed 1 mm. In chronic portal 
vein obstruction these plexus are dilated in response 
to portal hypertension leading to thickening of biliary 
duct walls and compression, often with a characteristic 
radiological/endoscopic image of virtual lumen[9-11]. In 
particular, dilation of plexus of Saint causes fine irregu-
larities in biliary walls while dilation of plexus of Petren 
causes extrinsic compression.
The ischemic damage seems to be related to defi-
cient portal blood supply of the biliary tree secondary 
to EHPVO and PC and to thrombosis of small bile duct 
venules, resulting in strictures formation and fibrous[9].
The prevalence of biliary strictures due to a mechanical 
compression is about 55% among patients with PB, 
on the contrary in 45% of cases there was no relation-
ship between stenosis localization and severity and 
cavernoma/collateral vein compression, suggesting the 
preponderance of ischemic damage in these cases[12]. 
However, both mechanisms can contribute at the same 
time in PB pathogenesis.
The bile stasis secondary to biliary strictures and 
hypothetic changes in bile compositions (increased 
pigment load due to hypersplenism, abnormal entero-
hepatic circulation of bile acids due to portal hyperten-
sion) can contribute to stones formation[13].
DIAGNOSIS AND CLASSIFICATION
The diagnosis of PB is based on radiological imaging, 
in particular on cholangiography. MRCP is a non-
invasive imaging test that can give a definite outline 
of biliary ductal abnormalities, and for these reasons 
it represents the modality of choice for PB diagnosis 
and evaluation. As previously mentioned, the main 
alterations evidenced at MRCP are bile duct stenosis, 
angulations and dilations, both intra and extra-hepatic, 
parietal irregularities, bile duct angulations, choledo-
chal varices, lithiasis[3,9]. Condat et al[3] purposed the 
use of MRCP coupled with magnetic resonance (MR) 
portography in the initial evaluation of PB, to assess 
both biliary abnormalities and portal anatomy, which 
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Core tip: Portal biliopathy in patients with portal vein 
thrombosis and portal cavernoma can be symptomatic 
in about 5%-38% of patients. Therapy includes 
endoscopic and surgical approaches aimed to improve 
both portal hypertension and biliary alterations and 
clinical manifestation. Usually, multiple and combined 
treatments are required to resolve portal biliopathy.
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INTRODUCTION
Portal biliopathy (PB) is a clinical condition defined 
as the presence of abnormalities in the biliary tree 
(including biliary tree and gallbladder) in patients 
with non-cirrhotic/non-neoplastic extrahepatic portal 
vein obstruction (EHPVO) and portal cavernoma 
(PC)[1]. In literature, this disease has been named as 
“portal hypertensive biliopathy”[2], “portal cavernoma-
associated cholangiopathy”[3], “portal cavernomachol-
angiopathy”[4], “cholangiopathy associated with portal 
hypertension”[5], “pseudosclerosing cholangitis”[6] and 
“pseudocholangiocarcinoma”[7] due to the fact that PB 
biliary alterations can mimic sclerosing cholangitis or 
cholangiocarcinoma, respectively.
The spectrum of biliary abnormalities shown at 
magnetic resonance cholangiopancreatography (MRCP) 
includes intra- and extra-hepatic biliary stenosis (single 
or multiple), with or without consensual above dila-
tion; bile duct wall irregularity or thickening; bile duct 
angulation, varicose veins located at the ductular walls 
and gallbladder[3,8].
The aim of this paper is to analyse PB clinical 
approaches based on classification and characteristics 
of portal biliopathy through a systematic review of the 
literature.
For this purpose, a systematic search on MEDLINE 
was conducted spanning April 1990 to April 2016. 
Studies were identified using the following terms: “por-
tal biliopathy” OR “portal cholangiopahty” OR “pseudo-
sclerosing cholangitis” OR “pseudocholangiocarcinoma” 
AND “treatment”. In addition, all study references were 
consulted to identify any other relevant studies. Only 
studies on humans were considered, and only papers 
wrote in English were used for the analysis. Inclusion 
criteria were as follows: patients with PB secondary 
to non-neoplastic non-cirrhotic portal vein thrombosis 
(PVT) reporting endoscopic and surgical treatment 
of PB, both case series and case reports. Exclusion 
criteria were: review articles, guidelines or comment 
to other papers; iatrogenic PVT articles; papers about 
treatment of PB therapy complications or PB medical 
helps in choice of the best therapeutic approach.
Initially, endoscopic retrograde cholangiopancrea-
tography (ERCP) has been for many years the modality 
of choice to obtain cholangiographic images. Nowadays 
it has been replaced by MRCP in biliary diagnostic: 
ERCP is an invasive tool with possible complications, 
and it has only a therapeutic rather than diagnostic 
role. ERCP abnormalities are the same demonstrated 
at MRCP, however some old studies that used ERCP for 
PB diagnosis described a more frequent and severe left 
hepatic duct involvement (40%-100%) respect right 
hepatic duct (40%-57%)[6,14].
Endoscopic ultrasound (EUS) has a complementary 
role and can evaluate biliary stenosis and dilations, 
stones, and in particular it is able demonstrate dilated 
peri-choledochal venous collateral vessels[15].
Abdominal ultrasound (US) has not a primary role 
in PB diagnosis but can be complementary to other 
techniques to evaluate presence and characteristics 
of PC, presence of gallbladder varices, signs of portal 
hypertension, gallstones, biliary tree dilation.
In the literature many classification have been 
published. Firstly, Chandra and Sarin[10] identified four 
PB types according with the biliary abnormalities locali-
zation at ERCP: type Ⅰ, involvement of extrahepatic 
bile duct only; type Ⅱ, involvement of intrahepatic 
bile duct only; type Ⅲa, involvement of extrahepatic 
bile duct and unilateral intrahepatic bile duct (left or 
right); type Ⅲb, involvement of extrahepatic bile duct 
and bilateral intrahepatic ducts. Llop et al[1] classified 
PB into different degrees of severity: grade Ⅰ, biliary 
tree irregularities or angulations; grade Ⅱ, indenta-
tions or strictures without dilation; grade Ⅲ, strictures 
with dilation (defined as intrahepatic duct ≥ 4 mm or 
extrahepatic duct ≥ 7 mm).
At least, Shin et al[16] distinguished three type of 
PB base on pathogenetic mechanism: they described 
a varicoid type in which biliary irregularities are mainly 
caused by extrinsic compression, a fibrotic type in 
which strictures are due to fibrosis and wall thickening 
that results from ischemic injury, and a mixed type 
(both kind of alterations and pathogenetic mechanisms 
are involved). 
CLINICAL MANIFESTATIONS AND 
NATURAL HISTORY
Biliary changes are present in about 77%-100% 
of patients with PC[1,3,6]; however, only 5%-38% of 
patients developed biliary symptoms[1,3,14]. Symptoms 
and clinical manifestations of PB can be related to 
chronic cholestasis and/or biliary stones formations, 
and they include jaundice, cholangitis, cholecystitis, 
abdominal pain, cholelithiasis[17].
Risk factors for symptoms occurrence in PB are 
older age, longer duration of disease, common bile 
duct and gallbladder stones, and abnormal liver func-
tion tests (LFTs)[18].
The natural history of PB is still undefined. Dhiman 
et al[11] identified four stages in PB progression, shown 
in Table 1. The progression from stage Ⅰ to Ⅳ is due 
to worsening of biliary changes, symptoms onset, 
alterations in liver function tests and complications 
occurrence. Only one study by Llop et al[1] investigated 
the evolution of biliary changes and symptoms in 
patients with acute and chronic non-cirrhotic non-
tumoral PVT: 67 patients were followed with MR 
angiography (MRA) and MRCP after PVT diagnosis. 
Among 22 patients with acute PVT, 73% developed 
biliary alterations at MRA/MR cholangiography (MRC) 
within a median follow-up of 33 mo (range 1-102): 4 
patients had grade Ⅰ PB, 4 grade Ⅱ and 8 grade Ⅲ, 
while 6 patient didn’t had PB. In 14 patients without 
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MEDLINE search:
“portal biliopathy” or “portal cholangiopathy” or 
“pseudosclerosing cholangitis” or 
“pseudocholangiocarcinoma” and “treatment”
40 papers excluded:
PB diagnosis: 3
PVT treatment: 6
PB complication treatment: 7
Comment to other paper: 2
No PB/PVT papers: 20
Articles not in English: 2
•
•
•
•
•
•
29 review papers excluded•
49 papers considered for the 
systematic review
78 papers
103 papers
63 papers, references consultation
Figure 1  Flow-chart of literature search. PB: Portal biliopathy; PVT: Portal vein thrombosis.
Franceschet I et al . Portal biliopathy management
grade Ⅲ PB, 11 performed another MR during a 43 
mo follow-up and no progression to grade Ⅲ PB was 
observed. Chronic PVT was present in 45 patients: 
within a median follow-up of 67 mo (range 0-749), 
80% developed PB (3 patients grade Ⅰ, 7 grade Ⅱ 
and 26 grade Ⅲ). Also in this group, no evolution from 
grade Ⅰ-Ⅱ PB to grade Ⅲ PB was observed after a 
mean follow-up of 37 mo. Biliary symptoms occurred 
in 41% of grade Ⅲ PB patients, while patients with 
grade Ⅰ-Ⅱ PB remained asymptomatic during follow-
up [Positive predictive value (PPV) 41%, Negative 
predictive value (NPV) 100%]. In conclusion, when PB 
is established due to the formation of PC in EHPVO, 
the clinical picture will not change much over time and 
clinical manifestations will be mainly correlate with site 
and type of stenosis.
THERAPEUTIC APPROACHES
Treatment of PB is recommended only for symptomatic 
patients, whereas the presence of biliary abnormalities 
associated with mild biochemical alterations without 
clinical manifestations is not an indication for therapeu-
tic intervention but requires a biochemical and clinical 
follow-up[11]. 
Therapy of portal biliopathy should be addressed 
to firstly reduce portal hypertension and secondly to 
resolve biliary obstruction. Both surgical and radiologi-
cal porto-systemic shunt (PSS) can be considered 
the treatment of choice to reduce portal hypertension 
in patients with EHPVO and PC; when PB is related 
only to a mechanical compression, this approach can 
resolve both PC and PB at the same time[19]. However, 
when the damage of the biliary tree is also ischemic, 
portal decompression alone is not sufficient to relief 
biliary obstruction, and in many cases patients need 
multiple endoscopic and surgical interventions on 
biliary tree during their life. An example of cholangi-
ographic findings at ERCP before and after endoscopic 
plastic stent placement is shown in Figure 2.
Medical treatment with ursodeoxycholic acid (UDCA) 
has a limited role, even if some authors reported reso-
lution or improvement of mild PB symptoms (mainly 
abdominal pain and biochemical cholestasis without 
evidence of stones) and prevention in recurrence of 
cholangitis after UDCA therapy alone[1,17,20].
At the moment, there is not a standardized flow-
chart for PB therapy, and data about different and 
combined approaches and their outcomes are reported 
from small series and case reports.
Considering all papers included in this review, a 
total of 284 PB patients were described, among these, 
the most frequent described symptoms were jaundice 
(52.8%), cholangitis (27.1%) and abdominal pain 
(19.4%). The mean age at PB presentation was 33.5 
± 13.5. 
Hereafter we analyze the different types of treat-
ment reported in the included articles.
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Stage Portal cavernoma Biliopathy LFTs Symptoms Complications
Preclinic yes No Normal No No
Asymptomatic yes Early changes Normal or abnormal No No
Symptomatic yes Advanced changes Abnormal yes No
Complicated yes Advanced changes Abnormal yes yes
Table 1  Characteristics of four stages in portal biliopathy natural history
LFTs: Liver function tests.
A B
Figure 2  Cholangiographic findings in a patient with symptomatic (jaundice and cholangitis) portal biliopathy secondary to chronic extrahepatic portal 
vein obstruction and portal cavernoma. Ischemic stenosis with dilatation of the left intrahepatic biliary tree is shown by ERCP (A): patient underwent unsuccessful 
ERCP with stent insertion and then PTBD placement; PTBD was changed for 3 times in one year because of cholangitis and liver abscess. After clinical and 
biochemical improvement of BA, patient was treated with surgical splenorenal shunt and after 5 mo PTBD was definitively removed. Last cholangiography obtained 
before PTBD removal shows significant improvement in biliary dilation (B). Patient is actually asymptomatic for BA and PB management. BA: Bilioenteric anastomosis; 
ERCP: Endoscopic retrograde cholangiopancreatography; PB: Portal biliopathy; PTBD: Percutaneous transhepatic biliary drainage.
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Endoscopic treatment
Among the total of symptomatic PB patients included 
in case series and case reports, 114 patients were 
treat endoscopically at first. Only in 34 patients (29.8%) 
a single endoscopic treatment resolved PB altera-
tions and symptoms; among these, 13 patients had 
common bile duct (CBD) stones as PB manifestation 
resolved after endoscopic sphincterotomy (ES) + stone 
extraction (SE). In most cases, repeated treatment 
were necessary to have a complete resolution of biliary 
abnormalities, often combined with surgical interven-
tion for portal hypertension: after the first treatment, 
49 patients (43%) underwent multiple plastic stent 
exchange, 4 (3.5%) metallic stent placement, 35 
(30.7%) surgical treatment with PSS or splenectomy 
(with or without esophageal devascularisation), 7 (6%) 
surgical biliary anastomosis, 2 (1.7%) transjugular 
intrahepatic porto-systemic shunt (TIPS) and 1 (0.9%) 
liver transplantation (LT). The duration of follow-up, 
when reported, range between 2 d and 18 years. In 
these cases the endoscopic approach can be con-
sidered safe, even if some complications have been 
reported. The most frequent is haemobilia, occurred 
in 24 procedures (in one case after intracholedocal 
biopsy). The risk of haemobilia during endoscopic 
treatment for PB is related to the presence of numer-
ous pericholedocal compensatory collateral veins and 
congestion of biliary duct walls vessels. In particular, 
the transient pressure elevation in the distal portion of 
biliary varices during balloon sweeping can increase the 
risk of bleeding[21]. For these reasons, a decompres-
sive shunting procedure performed before endoscopic 
treatment could reduce the risk of haemobilia[21,22].
Cholangitis were also frequent (reported after 53 
procedures), but although they can be seen after ERCP 
in up to 15.4% of cases[23], they are often not directly 
related to the endoscopic treatment but rather to 
recurrence of sludge or stones inside the biliary stent 
and can be treated with stent exchange. Sepsis was 
observed as well in 3 cases. Mortality directly related 
to endoscopic treatment was 0%, but one patient died 
for secondary biliary cirrhosis and one for cholangitis, 
both developed despite multiple stent placements dur-
ing the treatment period.
The choice of the endoscopic treatment of PB 
depends on the type of biliary alterations and includes 
ERCP with ES, SE (with previous mechanical lithotripsy 
if necessary) for patients with choledocholithiasis, 
stricture dilation ± biliary stent or nasobiliary drain 
placement.
The largest series of PB patients endoscopi-
cally treated is described by Saraswat et al[24], who 
published data about 130 ERCP performed for biliary 
strictures in 20 symptomatic patients. ES with SE was 
performed in 8 patients with choledochal stones and 
9 patients were treated with plastic stents placement. 
Eleven patients (for a total of 101 procedures) were 
treated on the line of postoperative benign biliary stric-
tures, with balloon dilation and plastic stent insertion, 
that were exchanged every 3-4 mo until LFTs normal-
izations; in 8/11 case a cholangiogram normalization 
was achieved as well. ERCP complications included 
haemobilia in 9/130 procedures and cholangitis in 
40/130 (mainly already present at the moment of 
ERCP and due to delay in stent exchanged). 
Khare et al[25] published a case series including 13 
patients with EHPVO and PC complicated by sympto-
matic PB divided in 3 groups according to radiological 
biliary findings: group A included 5 patients with biliary 
strictures without choledocholithiasis; group B included 
3 patients with choledocholithiasis alone; group C 
included 5 patients with both biliary strictures and 
choledocholithiasis. In group A, 4 patients were treated 
endoscopically with biliary stenting alone (n. 3) or with 
previous dilation (n. 1), followed by surgical PSS for 
portal hypertension. In 3/4 patients ERCP resolved 
biliary strictures, while 1 patient showed persistent 
stenosis at 12 mo and underwent multiple endoscopic 
procedures with dilation and stenting. In group B, 2/3 
patients were treated with endoscopic SE that was 
successful in one patient; the other patient underwent 
stent placement and then surgical intervention for por-
tal hypertension (splenectomy with esophagogastric 
devascularisation). During the follow-up, this patient 
needed multiple ERCP for choledochus clearance. In 
group C, four patients were first treated with endo-
scopic approach but SE failed in all of these patients; 
after surgical approaches (PSS or splenectomy with 
esophagogastric devascularisation), 2/4 patients were 
successfully managed with repeated ERCP with dilation 
and SE. No complications were observed after ERCP.
In 2009 the group from Birmingham published 
his experience with 13 patients with symptomatic 
portal biliopathy[17]: at the cholangiography (PB was 
diagnosed with MRC in 12 patients and with ERCP 
in 1), 12 patients showed biliary strictures, 10 bile 
duct stones/sludge, 11 gallbladder stones/sludge. In 
one patients symptoms (right hypocondrial pain and 
dark urine) resolved spontaneously, while 12 patients 
underwent therapeutic ERCP that was successful in 
8: in one patients with associated Crohn’s disease 
plastic stent insertion did not resolved jaundice and 
the patient, that was not eligible for surgical portal 
decompression for PVT extension, was listened for liver 
and small bowel transplantation; one patient had an 
excellent response to ES and SE. Among 7 patients 
with jaundice resolution after plastic stent insertion, 
2 patients underwent portal decompression for recur-
rent cholangitis despite multiple ERCP (one with PSS 
and one with TIPS), 1 needed repeated plastic stent 
changes and in 3 patients a metallic biliary stent was 
placed after several repeat plastic stent changes. 
Among 4 cases in which ERCP was unsuccessful, 2 had 
spontaneous resolution. The observed complications 
during a total of 49 ERCP were haemobilia (4%) and 
sepsis (6%, two cholangitis and one enterococcal 
sepsis), and no death directly related to biliary compli-
cations was observed during the follow-up.
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In particular, the last two articles evidence how 
complex is to choice the appropriate treatment for PB, 
and the great variability on patients response to the 
same therapy, even between patients with the same 
type of biliary manifestation. This is also due to the 
difficulty to classify the etiology of PB (varicoid type or 
fibrotic type) based on cholangiographic findings.
Combined treatment with biliary procedures and 
percutaneous transhepatic portal vein recanalization 
(balloon dilation + self-expandable stent placement) 
have also been reported[26].
The role of UDCA administration associated with 
endoscopic procedures is still uncertain: even if some 
authors reported the absence of biliary symptoms 
recurrence after endoscopic treatment associated with 
UDCA therapy[1,3], equally good results with the only 
endoscopic management are reported.
All published PB case series and case reports about 
endoscopic treatment of PB are summarized in Tables 
2 and 3[1,3,15,17,20,22-47], respectively.
Surgical treatment
Indication to surgery in PB patients is given by the 
need to decompress the portal system through PSS 
and to resolve the biliary obstruction. In cases in which 
PB is due to biliary compression by PC, the detension 
of collateral vessels obtained with the reduction of 
portal pressure by PSS can resolve in the same time 
biliary obstruction[30]. The most common PSS per-
formed are proximal spleno-renal shunt or mesocaval 
shunt, but other types of surgical shunts include 
meso-gonadal vein shunt, meso-renal shunt, right-
porto ovarian shunt, shunt between a portal varix and 
cava[41,48-51].
However, in patients without resolution of biliary 
abnormalities and symptoms after PSS, a second 
stage procedure can be required: biliary stenosis can 
be managed endoscopically, as explain above, or with 
surgical construction of a bilioenteric anastomosis. In 
patients without a suitable patent vein, splenectomy 
associated with esophagogastric devascularisation 
could reduce pressure in pericholedochal collateral 
veins and improve biliary symptoms[52]. A surgical 
approach with intrahepatic segment 3 bypass has been 
described to provide definitive treatment for biliary 
decompression and stone removal in a single time 
procedure in appropriately selected patients[47].
The largest PB series[52] retrospectively included 
56 PB patients who underwent surgery from 1996 to 
2010; 32/56 (57.1%) were asymptomatic for PB. To 
reduce portal hypertension, PSS was performed in 40 
patients and splenectomy with devascularisation in 16. 
After first-line surgery, 7 patients required endoscopic 
treatment for cholangitis or CBD stones, that was suc-
cessful in 2 patients, while 5 of them required multiple 
procedures; 2 patients previously treated with PSS at 
least needed biliary surgery for dominant CBD stricture 
that required frequent stent exchanges. In addition, 
the authors reported a significant reduction in serum 
biliary levels after first-line surgery (both shunt and 
no-shunt surgery) and alkaline phosphatases (shunt 
surgery), confirming that the resolution or improve-
ment in portal hypertension can be effective in reliev-
ing biliary obstruction.
Vibert et al[30] published a case series including 19 
symptomatic PB patients and propose an interesting 
3 steps approach: (1) biliary drainage and antibiotic 
therapy if cholangitis is present; (2) surgical PSS; 
and (3) biliodigestive anastomosis with hepatico-
jejunal anastomosis with Roux-en-Y. Patients were 
divided in two groups according to feasibility of PSS: 
10 patients were included in the PSS group, 9 patients 
in the no PSS (NPSS) group. In the first group, one 
patient with severe sepsis from cholangitis underwent 
percutaneous transhepatic biliary drainage (PTBD) with 
extraction of intrahepatic stones. Then, a splenorenal 
shunt was performed in all 10 patients. Mortality was 
nil, and complications rate was 27%, including one 
chylus fistula and 2 early thrombosis, successfully 
treated with anticoagulant therapy or angiographic-
guided pneumatic dilation. Initially, PSS was successful 
in biliary symptoms resolution in 70% of cases, but 
within 30 mo after PSS 5/10 patients required a bilio-
enteric anastomosis because of persistent jaundice or 
recurrent cholangitis. In the NPSS group, 3 patients 
were initially treated with endoscopic approach (1 ES 
and 2 plastic stent placement); PTBD was positioned in 
6 patients (in 3 cases because of recurrence of biliary 
symptoms after endoscopic treatment); biliodigestive 
anastomosis was performed in 4 patients. Among 
these, one patient initially treated with endoscopic 
stent placement, 2 patients initially treated with PTBD 
and 4 patients treated with biliodigestive anastomosis 
needed repeated transhepatic cholangioscopies to 
remove intrahepatic stones and to improve biliary 
drainage; except for 2 patients lost in follow-up, 
at long-term follow-up one patient died for severe 
cholangitis and haemobilia while other patients were 
asymptomatic.
Overall, 173 patients underwent surgery interven-
tion as first or second step for PB treatment: PSS was 
performed in 131 patients, PSS with splenectomy in 
7, splenectomy with devascularisation in 18, devas-
cularisation in 1 and 16 patients underwent biliary 
surgery (biliodigestive anastomosis, cholecystectomy, 
choledochotomy). The reported follow-up after surgi-
cal intervention ranged between 4 mo and 15 years. 
Considering patients underwent PSS alone as first 
treatment for PB, biliary symptoms relieve in 64.1% 
of cases, while in patients firstly treated with surgical 
biliary anastomosis, only in 30% of cases no other 
treatment was required. 
A total of 6 death was reported: 1 patients died 
after 10 years from splenectomy for recurrence of 
gastrointestinal bleeding, 1 patient died for decompen-
sated alcoholic cirrhosis, one for perforated duodenal 
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ulcer and one for cholangitis and haemobilia after 8.6 
years from biliodigestive anastomosis, 2 patients died 
for intraoperative bleeding during surgery on bile duct 
(choledocholithotomy and hepaticojejunostomy), sug-
gesting a higher risk of bleeding from biliary tree due 
to the presence of numerous compensatory collateral 
veins and the congestion of biliary and splanchnic 
venous system. Table 4[2,3,19,25,30,51-58] summarized 
papers about surgical intervention in PB patients.
TIPS
In addition to surgical PSS, a TIPS placement can be 
a valid alternative to improve portal hypertension. 
Since 1996, Görgül et al[59] observed the resolution 
of “pseudocholangiocarcinoma” sign after TIPS in 
3 patients. In a case report, a 45-years-old woman 
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Table 2  Endoscopic management of portal biliopathy: summary of case series 
Ref. No. of patients Biliary abnormalities First treatment Follow-up Further treatments Complications/
outcome
Bhatia et al[27], 1995 4 symptomatic Stenosis + stones 3
CBD stones 4
ES + SE + NBD 4 3-8 mo Multiple ERCP 4 None
Perlemuter et al[20], 1996 8 symptomatic Stenosis 8
CBD stones 2
Cholangitis 1
ES+NBD 3
BD 1
PSS 1
UDCA 2
6-60 mo Multiple ES 1 Death 2 (cholangitis 
1; stroke 1)
Condat et al[3], 2003 7 symptomatic Cholecystitis/right 
hypocondrial pain 4
Cholangitis 1
Stenosis 2
Cholecystostomy + SE 1
Stent 1
BA + PTBD 1
UDCA 4
4-25 mo - Haemobilia 1
Sezgin et al[28], 2003 10 symptomatic Stenosis 9
IE stones 1
ES + stent 10
NBD 4
BD 4
3.3 yr
(range 1-7)
Multiple ERCP 5 Haemobilia 1
Cholangitis 5
Death 1
Dumortier et al[22], 2003 6 symptomatic Stenosis 5
CBD stones 2
ES 5
BD 5
SE 2
Stent 1
10 mo (range 2 
d-18 mo)
Multiple ERCP + PSS 4 Cholangitis 1
Cholecystitis 4
Khare et al[25], 2005 13 symptomatic Stenosis 10
CBD stones 8
Stent 4
BD 6
SE 4
- PSS 8
BA 1
Multiple ERCP 2
Splenectomy + devasc 2
Death 1
Dhiman et al[29], 2007 12 symptomatic Stenosis 7
CBD stones 5
CBD varices 1
Mirizzi’ssdr 1
PSS 5
ES 3
ES + BD 2
Stent 4
19 mo (6-132 
mo)
Multiple ERCP in pts 
initially treated with 
stent
Cholangitis in 2 pts 
treated with stent
Vibert et al[30], 2007 19 symptomatic IE biliary dilation 9
IE stones 7
CBD stones 4
PSS group:
PTBD 1
SRS 10
NPSS group:
ES + stent 2
ES + SE 1
PTBD 6
BA 4
19 pts
8.3 yr
PSS group:
BA 5
NPSS group
PTBD 1 after ERCP and 
4 after BA
Resolution 17
Death 3
Oo et al[17], 2009 13 symptomatic Stenosis 13
CBD stones 10
GB stones 11
UDCA 1
Stent 7
ES + SE 1
Failed ERCP 4
2 yr
(1-18 aa)
Metallic stent 3
Stent exchange 2
PSS 3 (2 TIPS, 1 surgical)
LT 1
Haemobilia 2
Sepsis 3
Llop et al[1], 2011 14 symptomatic Stenosis 14
CBD stones 6
GB stones 2
ES + SE 6
ES + UDCA 2
Cholecystectomy 2
- Multiple ERCP 1
BA 1
-
Saraswat et al[24], 2013 20 symptomatic Stenosis 20
CBD stones 8
GB stones 6
ES + SE 8
Stent 9
BD + stent 11
18 mesi (range 
3-188)
Multiple ERCP 11 In 130 procedures:
Cholangitis 40
Haemobilia 9
Ramchandani et al[31], 
2013 
5 symptomatic CBD stenosis 2
CHD stenosis 1
CBD stones 2
Metallic stent 1
Plastic stent 2
BD + stent 1
Intracholedocal lithotripsy 1
6-7 mo SRS 2
Stent Exchange 1
- Resolution 5
Cellich et al[23], 2015 8 symptomatic
1 asymptomatic
Stenosis 7
CBD stones 3
GB stones 1
ES 7
BD 4
SE 2
Stent 7
- PSS 1
Stent exchange 3
BA 3
Cholangitis 3
Haemobilia 1
CBD: Common bile duct; GB: Gallbladder; IE: Intrahepatic; ES: Endoscopic sphincterotomy; SE: Stone extraction; NBD: Nasobiliary drainage; BD: 
Balloon dilation; PSS: Porto-systemic shunt; NPSS: No porto-systemic shunt; UDCA: Ursodeoxycholic acid; ERCP: Endoscopic retrograde cholangio-
pancreatography; BA: Bilioenteric anastomosis; SRS: Splenorenal shunt; LT: Liver transplantation; TIPS: Transjugular intrahepatic porto-systemic shunt.
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affected by cholestatic jaundice due to compression 
on CBD by extrahepatic portal and splenic vein throm-
bosis with collateral, was treated with TIPS: in order 
to decompress the biliary tree before the procedure, 
a biliary stent was placed and the day after TIPS was 
successfully performed. The biliary stent was removed 
after 1 wk and, at 14 mo follow-up, the patient was 
asymptomatic and MR/MRCP showed a significant 
improvement of biliary alterations and of cavernoma 
size[60]. Another case report described resolution of 
cholangiographic CBD abnormalities and normaliza-
tion of LFTs after TIPS performed in a patient with PB 
and portal hypertension secondary to PVT[61]. In the 
case series published by Cellich et al[23] including 13 
PB patients, one of these was initially treated with 
TIPS that was unsuccessful; patient underwent PSS 
and multiple endoscopic treatment and, at least, bil-
ioenteric anastomosis. Oo et al[17] reported 2 patients 
successfully treated with TIPS: one after repeated 
ERCP with plastic stent exchanges obtaining resolution 
of biliary symptoms and reduction in portal pressure; 
the second was successfully treated with temporary 
PTBD placement followed by TIPS. Even if the use of 
TIPS in PB patients is anecdotal, this technique seems 
effective and safe in treatment of portal hypertension 
and PB secondary to PC. However, due to the vascular 
alterations secondary to PC, TIPS is not always techni-
cally feasible.
LT
There are few data about LT for PB patients. In 
literature only 4 cases are reported (1 regarding a 
paediatric patient), 2 living donor LT and 2 deceased 
donor LT[62-65]. Indication for LT was secondary biliary 
cirrhosis, recurrent cholangitis (even with suspicion of 
cholangiocarcinoma) despite multiple endoscopic treat-
ments, often associated with gastrointestinal bleed-
ing[62-64]; Zhang et al[65] reported 3 successful living 
donor LT in 3 paediatric patients with PC, one of these 
with jaundice and evidence of dilated biliary duct due 
to PC compression, consistent with PB; however, in all 
3 cases the major indication for LT was deteriorating 
liver function ad recurrent gastrointestinal bleeding. In 
all the 4 cases of LT for PB the outcome was favourable 
after a follow up of 12-26 mo.
CONCLUSION
PB is a frequent complication in patients with chronic 
PVT and PC, however symptoms are present in a 
minority of cases and only symptomatic patients 
require therapy.
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Table 3  Endoscopic management of portal biliopathy: summary of case reports
CBD: Common bile duct; ES: Endoscopic sphincterotomy; SE: Stone extraction; BD: Balloon dilation; PSS: Porto-systemic shunt; IE: Intrahepatic; BA: 
Bilioenteric anastomosis; ERBD: Endoscopic retrograde biliary drainage; PTBD: Percutaneous transhepatic biliary drainage.
Ref. Patients Biliary abnormalities First treatment Follow-up Further treatment Complications
Mörk et al[32], 1998 2 CBD stenosis 2 Stent 2 - Multiple Stent exchange + PSS 1 Cholangitis 1
Solmi et al[33],
1998 
1 Stenosis Stent - - -
Mutignani et al[34], 
2002 
3 CBD stenosis 3 Stent 3 - PSS 3 Haemobilia 3
Perego et al[35], 2003 1 Stenosis + CBD stones - Stent 3 yr Multiple stent exchange→PTBD + 
dilation and SE
-
Umphress et al[15], 2004 M, 62 yr IE and CBD stones ES + SE + stent 1 yr Stent exchange and 
cholecistectomy
-
Guerrero Hernández 
et al[36], 2005 
M, 29 yrs CBD stenosis ERBD + Sugiura - - -
Rosenthal et al[37], 2008 F, 44 yr CBD stenosis and stones Stent + SE - PSS -
Ajayi et al[38], 2009 F, 13 yr Stenosis ES + BD + stent 6 mo Multiple stent exchange -
Layec et al[39], 2009 F, 74 yr Stenosis Metallic stent 18 mo Metallic stent Haemobilia
Sharma et al[40], 2009 M, 35 yr
F, 30 yr
M, 25 yr
CBD stenosis 3 ES+SE 3 - - Haemobilia 3
Vasiliadis et al[41], 2009 F, 39 yr CBD stenosis ES 19 mo Multiple stent exchange→PSS + 
cholecistectomy
-
Cantù et al[42], 2010 M, 31 yr CBD stenosis ES + stent 4 yr - -
Martinez et al[43], 2011 M, 34 yr IE diltaions Stent - - -
Mistry et al[44], 2012 M, 28 yr CBD stenosis BD + BA + PTBD - Percutaneous 
transhepatic-gastrostomy
Haemobilia
Alam et al[45], 2012 M, 30 yr
F, 19 yr
CBD stenosis 2
GB stones 1
CBD stones 1
PTBD
Stent
- Cholecistectomy -
D’Souza et al[46], 2013 M, 49 yr CBD stenosis Stent + BD (after stent removal) - PSS + splenectomy Haemobilia 
(post-biopsy)
Bernon et al[47], 2014 M, 36 yr CBD stenosis and stones SE + stent 1 yr Stent exchange→PTBD→
cholecistectomy, intrahepatic 3 
semgment bypass
Cholangitis
Hyun et al[26], 2015 M, 33 yr CBD stenosis ERBD→PTBD + portal stent 3 mo - Haemobilia
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The majority of patients with PC and PB need 
multiple treatments during their life, aimed both 
to decompress portal circle and to resolve biliary 
abnormalities and symptoms; only few patients have 
a complete resolution of biliary and vascular problem 
after the first intervention, and it can be seen more 
often in PSS performed for PC compressing the bile 
duct. In most cases a combined approach is required 
(endoscopy and surgery), but a consensus on the tim-
ing and priority of treatments is not still available.
In Figure 3 we propose a possible algorithm for 
the management of PB. For asymptomatic patients, 
no specific therapy is required except the eventual 
treatment of portal hypertension complications; during 
follow-up LFTs monitoring is suggested. For symptom-
atic patients, cholecistectomy is recommended in case 
of gallbladder stones or cholecistitis alone. In case of 
PB due to PC compression (varicoid type), surgical PSS 
or TIPS (when feasible) should resolve both PC and 
bleary stenosis. However, if cholangitis or choledoholi-
tiasis are present, they should be treated at first. In 
case of mixed type, an ischemic damage coexist with 
the compressive one and the only PSS will not solve 
the problem; in these case, further interventions on 
the biliary system are needed: consider ES with/with-
out stent placement and, in case of persistence of bili-
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Table 4  Surgical management of portal biliopathy: summary of case series and case reports
CBD: Common bile duct; GB: Gallbladder; IE: Intrahepatic; ES: Endoscopic sphincterotomy; SE: Stone extraction; BD: Balloon dilation; PSS: Porto-
systemic shunt; NPSS: No porto-systemic shunt; UDCA: Ursodeoxycholic acid; ERCP: Endoscopic retrograde cholangio-pancreatography; BA: Bilioenteric 
anastomosis; SRS: Splenorenal shunt; FU: Follow-up.
Ref. No. of patients Biliary abnormalities First treatment Follow-
up
Further treatments Complications/
outcome
Chaudhary et 
al[53], 1998 
9 symptomatic Stenosis: 2
CBD stones: 2
BA 2
SRS 7
9 pts
-
BA 2
Stent 1
ES + SE 2
Death 1
Resolution 7
Condat et al[3], 
2003 
7 symptomatic Cholecystitis/right 
hypocondrial pain 4
Cholangitis 1
Stenosis 2
Cholecystostomy + ERCP 1
Stent 1
BA+PTBD 1
4-25 mo - Haemobilia 1
Gauthier-Villars 
et al[19], 2005 
8 symptomatic 
(pediatric)
Stenosis 6
Biliarydilation 8
- PSS 8 8 pts
4.5-15 yr
- Complete resolution 7
Partial resolution 1
Khare et al[25], 
2005 
13 symptomatic A: Stenosis 5
B: CBD stones 3
C: Stenosis + CBD stones 5
A: PSS 4; BA 1
B: ERCP 2; PSS + BA 1
C: Unsuccessful ERCP 4; PSS 
3; Splenectomy + devasc 2
- A: Multiple ERCP: 1
B: Splenectomy 1 (post-ERCP)
C: Multiple ERCP 2; BA 1; 
Splenectomy + BA 1
Death 1
Vibert et al[30], 
2007
19 symptomatic IE biliary dilation 9
IE stones 7
CBD stones 4
PSS group:
PTBD 1
SRS 10
NPSS group:
ES + stent 2
ES + SE 1
PTBD 6
BA 4
19 pts
4-30 mo
PSS group:
BA 5
NPSS group
PTBD 1 after ERCP and 4 after 
BA
Resolution 17
Death 3
Dhiman et al[2], 
2007 
12 symptomatic Stenosis: 7
CBD stones: 5
Choledochal varices 2
Mirizzi’ssyndrome 1
PSS 5
ES 3
ES + dilation 2
Stent 4
19 mo 
(range 
6-132)
Multiple stent exchange in pts 
initially treated with stent
Cholangitis in 2 pts 
treated with stent
D’Souza et al[54], 
2009 
1 symptomatic CBD stenosis + GB stones Pre-surgery stent→PSS + BA 
(single stage)
18 mo - Resolution
Camerlo et al[51], 
2010 
3 symptomatic Stenosis 3 PSS 3
Stent 1 (pre-PSS)
3 pts
2-13 yr
- Resolution 3
Agarwal et al[55], 
2011 
39 symptomatic Stenosis 15
CBD stones 7
GB stones 12
IE dilation 39
SRS 37
BA 2
37 pts
32 mo
ES ± SE 10
BA 12
ES + cholecystectomy 1
Resolution 35
Chattopadhyay 
et al[52], 2012 
24 symptomatic
32 
asymptomatic
CBD stenosis 3
Multiple stenosis 5
IE dilation 14
CBD stones 7
GB stones 11
ERCP pre-surgery 12
PSS 40
Splenectomy + devasc. 16
43 pts
48 mo 
(range 
14-120)
ES + SE 2
Multiple ES + stent 5
BA 2
Resolution 38
Death 1
Suárez et al[56], 
2013 
3 symptomatic Stenosis 3 UDCA 1
BA 1
- - -
Bhatia et al[57], 
2014
2 symptomatic GB stones Cholecistectomy - - Resolution
Liu et al[58], 2015 18 Stenosis 6
Dilations 6
Stenosis + dilations 6
PSS 18 - - Resolution 15
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ary symptoms despite multiple endoscopic treatments, 
surgical intervention of bilioenteric anastomosis. When 
a fibrotic type of PB is diagnosed, PSS will not resolve 
the biliary alterations. In these cases, PB resolution 
is difficult to achieve and multiple endoscopic/surgi-
cal biliary treatments are required. Patients can be 
evaluated for LT in case of secondary biliary cirrhosis, 
recurrent cholangitis despite multiple endoscopic 
treatments or difficult control in portal hypertension 
manifestations.
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